

## **CATO RESEARCH SELECTS ARGUS SAFETY WEB™ FROM RELSYS**

*New pharmacovigilance system will enhance access by sponsors to clinical safety data and facilitate international submission of safety reports to regulatory agencies*

DURHAM, NORTH CAROLINA. – MAY 17, 2006 – Cato Research, a leading contract research organization, has selected Argus Safety Web™ 4.1 from Relsys International, including the Electronic Submission Manager, to provide its sponsors with the latest adverse event reporting technology.

Cato Research, an experienced provider of high-quality clinical trial services – from protocol development and site selection to clinical monitoring, pharmacovigilance and statistical analysis will use the drug safety solution as part of its pharmacovigilance practice. The organization's pharmacovigilance group provides full-service processing and reporting of serious adverse event (SAEs) for both clinical studies and post-marketing events for drugs, biologics and devices. In conjunction with its clinical, medical and regulatory teams, the pharmacovigilance group helps sponsors manage global safety effectively and efficiently.

“We're extremely proud that Cato Research has selected Argus Safety to be part of its global pharmacovigilance practice,” commented Dave Bajaj, President and CEO of Relsys International. “We've committed our company to develop global solutions for drug safety, and are gratified that we have been chosen by a leading CRO to help their sponsors move beyond adverse event collection and reporting and into a complete integrated environment for pharmacovigilance and risk management.”

For more information about the comprehensive range of services offered by Cato Research Pharmacovigilance, visit <http://www.cato.com/pharmaco.nsf/vwPages/Home?OpenDocument>.

### **About Cato Research Ltd.**

Founded in 1988 by Dr. Allen Cato and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, and medical device industries. Services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. With a staff of 300 and offices located in the United States, Europe, Canada, Israel, and South Africa, the Cato Research team consistently demonstrates an unsurpassed level of responsiveness, flexibility, attention to detail, and passion for bringing their clients' products to market rapidly and cost-effectively. For more information, visit Cato Research's website at [www.cato.com](http://www.cato.com).

### **About Relsys International**

Relsys International provides a complete systems solution for pharmacovigilance and risk management that help pharmaceutical, biotech and medical device companies improve drug safety and ensure ongoing compliance with global regulations. The company, founded in 1987, works in partnership with its customers to develop and deliver innovative solutions to long-term business needs, and to provide critical components to support its clients' corporate risk management strategies. Argus Safety,<sup>TM</sup> the company's flagship product, is the world's best selling adverse event reporting software, and is used by more of the leading pharmaceutical companies than any other solution. Relsys is a privately held company, headquartered in Irvine, California. For more information, visit [www.relsys.net](http://www.relsys.net).

**For more information, please contact:**

#### **Cato Research**

Allen Cato, M.D., Ph.D. Phone:  
919-361-2286 Fax: 919-361-  
2209 E-mail: [acato@cato.com](mailto:acato@cato.com)